Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 6:38:14940.
doi: 10.3389/ti.2025.14940. eCollection 2025.

One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study

Affiliations

One-Year HbA1c Predicts Long-Term Pancreas Graft Survival Following SPK Transplantation: A US Population Cohort Study

Georgios Kourounis et al. Transpl Int. .

Abstract

Understanding which factors shape long-term pancreas graft outcomes after the critical first year post-transplantation is an ongoing challenge. This study assesses one-year HbA1c as a predictor of subsequent pancreas graft survival. A retrospective cohort study was conducted using the UNOS registry on all simultaneous pancreas-kidney (SPK) transplants between 2017 and 2023. Regression models with multiple imputations for missing data were used to evaluate predictors of long-term function. Non-linear relationships were modelled with restricted cubic splines (RCS). Among 2,917 SPK recipients (median follow-up 44 months, IQR: 25-60), one-year HbA1c was the strongest independent predictor of long-term graft survival. An HbA1c of 6.8% versus 4.4% (95th vs. 5th percentile) was associated with significantly worse graft survival (aHR = 2.48, 95% CI: 1.72-3.58). Simulated trial sample size calculations found that detecting a statistically and clinically significant reduction in one-year HbA1c from 7% to 6.5% would require 65 patients per group, whereas detecting a reduction in one-year graft loss from 12% to 9% would require 1,631 patients per group. HbA1c at 1 year is a robust, continuous marker of long-term graft function and may serve as a feasible, objective surrogate endpoint in future clinical trials, enabling smaller, more efficient study designs to evaluate interventions.

Keywords: glycosylated hemoglobin (HbA1c); graft survival; long-term outcomes; pancreas transplantation; simultaneous pancreas-kidney transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of recipients included in the study.
FIGURE 2
FIGURE 2
(A) Histogram showing the distribution of 1-year HbA1c levels in the study cohort; (B) Kaplan-Meier survival curves illustrating crude univariable long-term graft survival over days post- transplantation (starting from 1 year after transplantation), stratified by HbA1c levels of <5.7% and ≥5.7%.
FIGURE 3
FIGURE 3
Model terms ranked by significance in predicting long-term pancreas graft survival.
FIGURE 4
FIGURE 4
Adjusted hazard ratio for pancreas graft survival based on recipient (A) HbA1c (% DCCT) and (B) eGFR (mL/min/1.73 m2) at 1 year. The non-linear relationship is shown with restricted cubic splines analysis. HbA1c was modeled with 4 knots, while eGFR used 3 knots.
FIGURE 5
FIGURE 5
Sample sizes required to detect the desired minimum clinically important difference across the range of values on the x-axis (A) a change in one-year mean HbA1c from 7% (e.g., a reduction from 7% to 6.5% would require 65 patients per group) and (B) a relative risk reduction in graft loss from 20% at 1 year (e.g., a reduction from 20% to 16% would require 1,444 patients per group).

References

    1. Dagogo-Jack S. 2015 Presidential Address: 75 Years of Battling Diabetes--Our Global Challenge. Diabetes Care (2015) 39(1):3–9. 10.2337/dc15-1818 - DOI - PMC - PubMed
    1. Gruessner AC, Gruessner RWG. The 2022 International Pancreas Transplant Registry Report—A Review. Transpl Proc (2022) 54(7):1918–43. 10.1016/j.transproceed.2022.03.059 - DOI - PubMed
    1. Gruessner AC, Gruessner RWG. Long-Term Outcome After Pancreas Transplantation: A Registry Analysis. Curr Opin Organ Transpl (2016) 21(4):377–85. 10.1097/MOT.0000000000000331 - DOI - PubMed
    1. Nathan DM, DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care (2014) 37(1):9–16. 10.2337/dc13-2112 - DOI - PMC - PubMed
    1. Boughton CK, Hovorka R. The Role of Automated Insulin Delivery Technology in Diabetes. Diabetologia (2024) 67(10):2034–44. 10.1007/s00125-024-06165-w - DOI - PMC - PubMed

Substances

LinkOut - more resources